Stocksigma LogoStocksigma Logo

Vineet Laboratories Reports Zero Deviation in Rights Issue Fund Utilization for Sep'26

Vineet Laboratories reported nil deviation in the utilization of proceeds from its ₹29.97 crore rights issue for the quarter ended 30th Sep'26

Vineet Laboratories Reports Zero Deviation in Rights Issue Fund Utilization for Sep'26

Vineet Laboratories Ltd · Others (Uncategorized) · 13 Nov 2026, 6:56 pm

Vineet Laboratories Reports Zero Deviation in Rights Issue Fund Utilization for Sep'26 Vineet Laboratories reported nil deviation in the utilization of proceeds from its ₹29.97 crore rights issue for the quarter ended 30th Sep'26. Of the total allocation, the company fully deployed ₹2.84 crore toward bank loan repayment and ₹6.71 crore toward general corporate purposes (against ₹6.71 crore allocated). Additionally, it utilized ₹8.88 crore out of ₹16.95 crore earmarked for production facility expansion and ₹0.34 crore out of ₹2.70 crore allocated for setting up an effluent treatment plant. CRISIL Ratings monitored the issue.

Original exchange filing (PDF)

More announcements from Vineet Laboratories Ltd

All Vineet Laboratories Ltd announcements